June 29th, 2006
New research at Saint Louis University found that placing a warm blanket on patients undergoing PET/CT scans to detect cancer, makes the test more accurate.
In up to 9 percent of patients, doctors have difficulty interpreting scans because of the presence of brown adipose tissue, also known as brown fat, which may lead to a cancer […]
By Gloria Gamat -- 0 comments
June 28th, 2006
According to a new study headed by the University of Colorado at Boulder, the chemical compounds in household products (like mothballs and air freshener) are carcinogens because they block the normal process of “cell suicide” in living organisms.
Naphthalene in mothballs and para-dichlorobenzene (PDCB) contained in some air freshener were found to block enzymes involved in […]
By Gloria Gamat -- 1 comment
June 27th, 2006
According to a study by researchers from the University of Southern California, a new prognostic test will be able to help determine if a prostate cancer patient will have a recurrence of the disease later on, even if the surrounding lymph nodes initially appear negative for cancer.
Current trials for the test developed at USC are […]
By Gloria Gamat -- 0 comments
June 26th, 2006
Paclitaxel (Taxol), a widely used chemotherapy drug can lose the fertility in male cancer patients. In a study presented at that 22nd annual conference of the European Society of Human Reproduction and Embryology in Prague, Czech Republic on Tuesday 20 June 2006, it may be possible to protect the testes of cancer patients by injection […]
By Gloria Gamat -- 0 comments
June 24th, 2006
Xanthohumol is a flavonoid found in hops (a beer ingredient) whose anti-cancer activity was first discovered 10 years ago by a team from Oregon State University.
These days some brewers are marketing products enriched in this compound (like Germany’s Xan), the researchers warned that beer is unlikely to provide any anti-cancer benefits.
“Beer is the major dietary […]
By Gloria Gamat -- 0 comments
June 23rd, 2006
In a study presented at the recent annual meeting of the American Society of Clinical Oncology (ASCO), researchers from the Ireland Cancer Center of University Hospitals of Cleveland headed by Afshin Dowlati, MD (hematologist/ oncologist) reported that they have found a promising, novel biomarker that may be used to predict the survival of patients with […]
By Gloria Gamat -- 0 comments
June 22nd, 2006
According to the final results from a national phase II trial of the Southwest Oncology Group study, led by UC Davis Cancer Center researchers, the new molecularly targeted agent bortezomib when added to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer.
Bortezomib, developed by Millennium Pharmaceuticals, […]
By Gloria Gamat -- 0 comments
June 21st, 2006
Metastatic renal cell carcinoma (mRCC) or advanced kidney cancer’s initial therapy is the current standard cytokine treatment. In a new study from Memorial Sloan-Kettering Cancer Center, the drug sunitinib malate (Sutentョ) was found more effective than the current standard treatment in treating advanced kidney cancer.
“This drug has shown more activity as a single agent against […]
By Gloria Gamat -- 0 comments
June 20th, 2006
Gleevec is the standard treatment for chronic myeloid leukemia. When patients failed to respond to this treatment, an experimental drug called Dasatinib, under development by Bristol-Myers Squibb was able to reverse the signs and symptoms of the disorder.
These findings from the phase I clinical trial that evaluated the safety and toxicity at different dose levels […]
By Gloria Gamat -- 0 comments
June 19th, 2006
Upon following a moderate, home-based exercise program using resistance bands and walking, breast and prostate cancer patients had less fatigue during radiation treatments, greater strength and could walk farther and faster in only four weeks.These were discovered by researchers in a pilot study at University of Rochester Medical Center.
Exercise is indeed becoming a new therapeutic […]
By Gloria Gamat -- 0 comments
Recent Comments